A Phase I Study of Hu5F9-G4 Immunotherapy in Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Full Title

A First-in-Human Phase 1 Dose Escalation Trial of HU5F9-G4 in Patients With Advanced Solid Malignancies

Purpose

The purpose of this study is to assess the safety and preliminary effectiveness of the investigational drug Hu5F9-G4 in patients with cutaneous T-cell lymphoma that has continued to grow or came back despite prior treatment. Hu5F9-G4 blocks a protein on cancer cells called CD47. Cancer cells use CD47 to protect themselves from the immune system. It is hoped that by blocking CD47, the immune system will be better able to recognize and destroy cancer cells.

Hu5F9-G4 is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have cutaneous T-cell lymphoma that has continued to grow or came back despite prior treatment.
  • At least 2 weeks must pass between the completion of previous therapies and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Steven Horwitz at 212-639-3045.

Protocol

16-1533

Phase

I

Investigator

Co-Investigators